Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focuses on Pioneering New Technologies

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in drug-delivery platforms focused on its patented DehydraTECH-based, drug-delivery technology and formulation development. A recent article discussing the company reads, “Earlier this year, Lexaria moved into its new head office that includes a Health Canada-licensed research and development laboratory that is being used to conduct world-leading research into drug-delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug-delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://ibn.fm/cWL3T). . . . Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.”

To view the full article, visit http://ibn.fm/YBVxA

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Reports 58% Revenue Increase; Notes Business Highlights for Q3 2019

  • POAI sees Q3 2019 revenue total $522,696 from $329,930 in Q3 2018
  • Company reports records sales of proprietary systems, supplies
  • Significant business highlights indicate continued momentum as Predictive Oncology looks to bright future

Predictive Oncology Inc. (NASDAQ: POAI), an artificial intelligence (AI) and data-driven functional precision medicine company, released its financial results for Q3 2019, and the numbers are impressive, including quarter revenues increasing 58% year over year (http://ibn.fm/TmZoV). The company also provided a business update outlining significant highlights reached during the quarter.

POAI reported that revenue for the quarter ended September 30, 2019, totaled $522,696, compared with $329,930 for the same period of 2018. Those numbers included revenue from record sales of the company’s STREAMWAY systems and disposable supplies. Predictive Oncology reported the sales of 19 STREAMWAY systems, a significant increase when compared to 10 sales of the system during the comparable period in 2018.

Cost of sales for Q3 2019 was $208,096 compared to $83,006 in the same period of 2018. Gross profit margin declined to 60% percent versus 75% in the third quarters of 2019 and 2018 respectively. Operating expenses for the quarter ended September 30, 2019, totaled $707,414 down from $723,939 for the third quarter of 2018. General and administrative expenses were $2,616,991 for Q3 2019, compared to $762,603 during Q3 2018. Sales and marketing expenses declined significantly, totaling $434,955 in Q3 2019 compared to $621,465 for the previous year.

In addition to the impressive numbers, POAI noted several Q3 2019 business highlights, including the following:

  • Initial models in progress with Interpace Diagnostics for Thyroid
  • Helomics has initiated pilot sequencing of 48 samples
  • ChemImage working on additional validation utilizing POAI platform and AI (D-CHIP) in prostate cancer
  • Specicare ‘Pioneer’ Precision Medicine trial in progress
  • Predictive Oncology continues to execute on Cancer Quest 2020
  • POAI subsidiary TumorGenesis has initiated the building of media kits to allow the growth of ovarian cancer cells in its labs.
  • Clinically validated, patient-derived (PDx) tumor profiling platform to generate drug response profiles and multi-omic data
  • Data on drug response profiles of more than 150,000 tumors across 137 cancer types using the PDx platform in more than 10 years of clinical testing.

“I am very pleased with the growth and development of our unique assets, Helomics and Tumor Genesis, and the increase in international interest in our Skyline products,” POAI CEO Dr. Carl Schwartz stated in a news release. “The future looks very bright.”

Predictive Oncology is committed to the mission of improving the standard of care for cancer patients through innovative, data-driven products and services. The company provides predictive models of tumor drug response to improve clinical outcomes for patients. POAI is at the vanguard of the latest scientific endeavors in cancer research to better understand the complexities of individual cancers and tailor individualized therapeutic protocols.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – SRAX, Inc. (NASDAQ: SRAX) Achieves Significant Sales Increase in Q3 2019

SRAX (NASDAQ: SRAX), a digital-marketing and consumer data-management technology company, recently reported financial results for the three months ended September 30, 2019. An article discussing the company reads, “On the financial side, the company saw a vertical sales increase of 17% along with a net income of $1.4 million (http://ibn.fm/99oDl). These gains arose out of a critical quarter for the company that included multiple milestones, including a full integration for international users and the first steps in the process of offering BIGtoken in multiple languages. . . .Christopher Miglino spoke about the traction that the company’s platforms are gaining, noting that ‘sales from existing platforms grew 11% and 17%, for Q3 2019 compared to Q2 2019 and Q3 2018, respectively, and are already benefiting from advances in BIGtoken.’”

To view the full article, visit http://ibn.fm/2ORuh

About SRAX Inc.

SRAX is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) Receives Health Canada Approval for Licensing of 16 Additional Cultivation Rooms Under Cannabis Regulations

Organigram Holdings (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “company” or “Organigram”), a leading licensed producer of cannabis, today announced the company’s receipt of Health Canada’s approval for the licensing of 16 additional cultivation rooms under the Cannabis Regulations. According to the update, the expanded license was effective as of December 12, 2019, and the new cultivation rooms represent approximately 13,000 kg/yr1 of increased target cultivation capacity. “This is a dynamic time for Organigram and the industry as a whole. Cannabis 2.0 – the legalization of adult use recreational cannabis edibles, vape products, extracts and topicals – is a new era for cannabis here at home and around the world,” Organigram CEO Greg Engel said in the news release. “Our physical expansion reflects our ambitious response to this new opportunity as well as our ongoing commitment to anticipating and meeting the demands of Canadian cannabis consumers for new and innovative cannabis experiences.”

To view the full press release, visit http://ibn.fm/PE1mj

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.Organigram.ca.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Organigram Holdings Inc. OGI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Key Player in AI Implementation in Ovarian Cancer Detection

  • POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world
  • Company’s work designed to speed development of new drugs, provide therapeutic choices
  • Helomics recently signed collaborative agreement with UPMC-Magee to establish data- and artificial-intelligence-driven approach to treating ovarian cancer

The power of artificial intelligence (AI) to assist in the detection of ovarian cancer much earlier than previously possible is being recognized worldwide. A company in the United Kingdom is touting the ability of AI to eliminate late detection of ovarian cancer, thanks to advancements in health-care technology (http://ibn.fm/AOmHt). The contribution AI is making in the detection of ovarian cancer has been a longtime, consistent focus for Predictive Oncology Inc. (NASDAQ: POAI) as well.

Predictive Oncology recently began sequencing ovarian cancers as part of its CancerQuest 2020 project and is building the largest ovarian multi-omic database in the world, designed to speed the development of new drugs and provide better therapeutic choices. Predictive Oncology’s subsidiary, Helomics, is vital to the CancerQuest2020 work POAI is doing in the ovarian cancer space.

Helomics currently has approximately 150,000 cases on its molecular information platform, 38,000 of which are specific to ovarian cancer. This invaluable scientific asset positions POAI as a leader in providing the critical molecular information needed for more effective patient treatments and new drug discovery.

As part of its CancerQuest 2020 project, Predictive Oncology, through Helomics, recently signed a collaborative agreement with UPMC-Magee to establish a data- and artificial-intelligence-driven approach to treating ovarian cancer. Based on the agreement, the partnership is designed to validate the significant value of using AI-powered decision-making for identifying specific treatments on specific genotypes to predict clinical outcomes for ovarian cancer patients.

Helomics has also begun sequencing retrospective ovarian cancer cases from the UPMC-Magee collaboration (http://ibn.fm/I4Lnb). As part of the sequencing process, Helomics is analyzing the mutations in the tumor (genome) and the expression of genes (transcriptome) in order to build a comprehensive multi-omic picture of the tumor. That information can then be brought together with Helomics’ data set of drug-response profiles to build an AI-driven predictive model of ovarian cancer.

“We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome,” Helomics CTO Dr. Mark Collins stated in a news release.

In addition to its ovarian-cancer data, Helomics has another 120,000 tumors with drug-response data across 137 cancer types that include lung, breast, pancreatic, colon and head and neck. Moving forward, the company intends to sequence all the tumors and build out predictive models in these additional disease categories. Once this work is complete, Helomics will have the largest pan-cancer, multi-omic database with drug responses in the market.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Predictive Oncology Inc. POAI | Leave a comment

ChineseInvestors.com Inc. (CIIX) Subsidiary Featured in WSJ Report on China’s Growing Cannabis Industry

  • ChineseInvestors.com is foremost financial information website for Chinese-speaking investors in U.S. and China
  • CIIX subsidiary was featured in a recent Wall Street Journal report on China’s growing cannabis industry
  • ChineseInvestors.com has highly diversified revenue streams that contribute to consistent, stable growth

ChineseInvestors.com Inc. (OTCQB: CIIX) offers an array of investor-education products and services and has become a top financial-information website for Chinese-speaking investors in the United States and China. At the heart of the approach is the ChineseInvestors Method, an inventive integration of a disciplined investing process, web-based tools, personalized instructions and support. In addition, the company is working to capitalize on the increasing demand for CBD (cannabidiol)-based nutrition and health products.

Established in 1999 and headquartered in San Gabriel, California, ChineseInvestors.com provides real-time market commentary, analysis and educational-related services in Chinese language character sets. In addition, CIIX offers consultative services to smaller private companies considering becoming a public company, as well as advertising and public-relations-related support services. Furthermore, the company provides retail, online and direct sales of hemp-based products and other health-related products.

Recently ChineseInvestors.com subsidiary, CBD Biotech Inc., was featured in a Wall Street Journal report on the growing cannabis industry in China (http://ibn.fm/c4TUI). The November 13 article was titled ‘China Says No to Marijuana but Lets Its Cannabis Industry Bloom’.

According to the WSJ report, “The CBD market will grow by 700% in the U.S. this year and will be worth more than $23 billion by 2023.” The report highlights CBD Biotech, which is a first mover in the industrial hemp skin-care and cosmetics industry. CBD Biotech is working to educate consumers on the benefits of industrial-hemp extract. Additionally, this subsidiary is also positioning itself to be one of the leaders in China’s legal market for skin-care products and cosmetics infused with cannabis sativa leaf extract, or industrial hemp extract. Cannabis sativa leaf extract can legally be added to skin-care and cosmetic products.

“As one of the first movers in the legal industrial hemp skin-care and cosmetics market, we are honored to be featured in this recent Wall Street Journal report and believe that this mention validates our efforts in China over the past few years,” CBD Biotech CEO Summer Yun stated in a news release.

ChineseInvestors.com has launched the world’s first online CBD health-products store published in the Chinese language: www.ChineseCBDOil.com. The company has done this under a wholesale agreement with a reputable CBD health brand. Through this website, the company sells CBD-infused products by way of online and in-store (http://ibn.fm/LTvQN).

Overall, ChineseInvestors.com’s plan is to focus on its original mission of providing financial information and services to the larger Chinese community in the United States and elsewhere. Of note to investors regarding the company’s CBD initiatives is that ChineseInvestors.com CEO Warren Wang indicated that the company hopes for a Nasdaq IPO of CBD Biotech late in 2019 or early 2020 (http://ibn.fm/kwEnA). Following that, the company would concentrate on identifying an acquisition target for further growth. FinTech products and services and CBD initiatives contribute to the varied revenue streams of ChineseInvestors.com.

ChineseInvestors.com continues to help investors make informed investment decisions and meet their individual financial goals. The company is also at the vanguard of capitalizing on the convergence of CBD and the nutrition- and health-products market in mainland China. ChineseInvestors.com offers investors diverse revenue streams for potential portfolio growth.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Chineseinvestors.com, Inc. CIIX | Leave a comment

MissionIRNewsBreaks – Why Sigma Labs Inc. (NASDAQ: SGLB) Is ‘One to Watch’

Sigma Labs (NASDAQ: SGLB), a leading developer of quality-assurance software for the commercial 3D printing industry, enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality and avoid rejects through its in-process quality-assurance software. A recent article discussing the company reads, “Sigma Labs, with its PrintRite3D(R) brand, has established a new benchmark in the development and commercialization of real-time, computer-aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality-control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance during production, uniquely allowing errors to be corrected in real time. . . . Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal-printing technology and the costly, inconsistent, quality-control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process, quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high-precision, quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.”

To view the full article, visit http://ibn.fm/uZF88

About Sigma Labs

Sigma Labs Inc. (NASDAQ: SGLB) is an emerging provider of quality-assurance software to the commercial 3D-printing industry under the PrintRite3D brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (“CAI”) solutions known as PrintRite3D for 3D, advanced-manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Sigma Labs Inc. SGLB | Leave a comment

Sigma Labs Inc. (NASDAQ: SGLB) Demos Exclusive Software Platform to Key Industry Players at Leading Global Additive Manufacturing Conference

  • SGLB’s PrintRite3D Real-Time Melt Pool Analytics software platform drew attention of industry elite at top international event
  • PrintRite3D version 5.2 contains new features, enhancements that further strengthen already impressive offering
  • Rising attendance, interest in event demonstrates elevated importance of, new opportunities in additive manufacturing

Sigma Labs Inc.’s (NASDAQ: SGLB) exclusive, in-process quality-control platform for metal-additive manufacturing was featured at the SGLB booth at Formnext 2019, the industry’s premier global conference held November 19-22, 2019, in Frankfurt, Germany. SGLB, the leading developer of quality assurance software for the commercial 3D metal-printing industry, participated at the event, where more than 850 exhibitors and almost 35,000 attendees gathered to view an impressive display of digital manufacturing capabilities.

SGLB chief technology officer Darren Beckett demonstrated the company’s proprietary PrintRite3D(R) Real-Time Melt Pool Analytics software platform at the premier global exhibition and conference (http://ibn.fm/yYaQQ). Renowned for showcasing the next generation of intelligent industrial products, Formnext was the perfect forum to shine a worldwide spotlight on Sigma Labs’ latest PrintRite3D offering.

PrintRite3D version 5.2 contains new features and enhancements that further strengthen the usability and capabilities of the software to support the industrialization of additive manufacturing for serialized production. PrintRite3D’s new features include the following:

  • Automated anomaly detection with Z connectivity, which identifies thermal anomalies that propagate across multiple layers
  • Enhanced detail data trend analysis
  • Customizable thresholding to enable automatic user alerts
  • Real time user alert notifications for identified thermal anomalies exceeding specification limits

At Formnext 2019, Beckett presented several live demonstrations of PrintRite3D to industry executives attending the prestigious event. Beckett was also available for technical reviews.

“This leading industry event for additive manufacturing and modern industrial production grows every year, clearly demonstrating the elevated interest and new opportunities ahead in additive manufacturing,” Beckett said. “It’s an exciting time for Sigma Labs as a leader in the field.”

Formnext 2019 is a leading global trade fair dedicated to additive manufacturing and industrial 3D printing. The Frankfurt event brought together the industry’s elite from 34 nations. SGLB was able to reach market leaders such as, Materialise, Additive Industries, Addup, DMG Mori, EOS, GE, Materialise, Matsuura, , Renishaw, Siemens, SLM Solutions, Trumpf, Panasonic, Mitsubishi, United Technologies, Rosswag, Volkswagen, Fraunhofer, BASF, Safran, Baker Hughes, GKN, Stryker, Coherent Laser, Oerlikon, Airbus, Nikon, Zeiss and many more.

Formnext functions as a significant business platform for industry players at which many companies conduct concrete business transactions directly on the exhibition floor (http://ibn.fm/EX7fC). As the growing additive manufacturing industry continues to evolve, it is likewise attracting a growing number of investors. At Formnext 2019, “there was a significant increase in interest from venture capital companies and industrial companies who, for example, would like to become strategic partners for young companies.”

Sigma Labs Inc. is a leading provider of quality assurance software to the commercial 3D-printing industry under the PrintRite3D brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection solutions for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, thereby allowing errors to be corrected in real time.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sigma Labs Inc. SGLB | Leave a comment

Sigma Labs Inc. (NASDAQ: SGLB) Revolutionizes 3D-Printing Industry with Breakthrough Quality-Assurance Software

  • Software pioneer Sigma Labs’ offers first known, real-time, computer-aided inspection (CAI) technology that enables in-process intervention
  • PrintRite3D overcomes quality assurance obstacles that hinder 3D metal printing from becoming fully integrated into modern manufacturing lines
  • Sigma Labs’ PrintRite3D enables real-time monitoring, analysis, feedback and control during the 3D-printing process of precision metal parts

Sigma Labs Inc. (NASDAQ: SGLB) is a leading producer of quality assurance software for the commercial 3D-printing industry. The company is about to revolutionize commercial 3D printing metal by enabling nondestructive quality assurance during the production process. Sigma Labs’ proprietary PrintRite3D software is a real-time, computer-aided inspection (CAI) technology long sought by 3D printing companies to lower costs and increase yields. PrintRite3D represents a breakthrough in the 3D-quality inspection sphere because it is the only known real-time, in-process, quality-assurance software for the commercial 3D metal printing industry.

3D printing, also called additive manufacturing, is a technology that allows producers to transform a 3D digital model of an object into a physical one by adding material rather than subtracting it, hence the additive in the name. The resulting 3D objects are made in a digitally controlled and operated process by depositing minuscule layers of material onto a substrate layer.

The technology has been embraced by commercial users, especially aerospace. The technology allows companies to build digital designs, push ‘Send’ and render fully formed prototype, customized products or commercial parts in volume – all while saving money, manpower, weight and time. However, the technology is facing hurdles in finding its way beyond prototyping and into conventional manufacturing and serial production. The reason? Before 3D printing metal can be fully integrated into modern manufacturing lines, technology is needed to resolve significant issues such as optimized data handling as well as real-time quality assurance process, monitoring and control.

Due to variances in the 3D-printing process, consistent quality of produced parts can’t be reliably achieved without considerable postproduction inspection that results in high rejection costs. Because parts are inspected after production using expensive CT scans, the manufacturer doesn’t know until the end of the process which of the finished parts meet design specifications. This results in lost time, lost profits and inability to economically scale up production.

This is where Sigma Labs steps in. The company’s people, processes and technologies are pioneers, about to transform the nascent 3D-printing sector by enabling SGLB’s rapid, efficient commercial applications and allowing growth at scale. Unlike any other quality-inspection software in the market, PrintRite3D is a third-party, validated software that enables real-time monitoring, analysis, feedback and control during the 3D-printing process of precision metal parts. The software conducts thermal-signature anomaly detection and automatic risk-level classification through statistical process sampling and advanced analytics.

This innovative solution is based on a proactive, comprehensive, process-focused methodology that enables prediction of product conformance to predefined acceptance requirements. More simply, PrintRite3D discovers defects during the production while adjusting the process in real-time to correct them. This unique solution leads to faster production of metal parts with fewer errors and a more uniform product resulting in decreasing downtime and waste while increasing yield and profits for 3D-printing companies.

3D printing is an innovative technology that has seen growing interest from manufacturers and investors alike stemming from decreasing product lifecycles trend, which is influenced by factors such as increased global competition and the need for innovation due to saturated markets and changing customer demands. Additive-manufacturing technology is viewed as a response to these challenges as it considerably reduces time to market.

According to Verified Market Research, the global 3D-printing market was valued at $8.08 billion in 2017 and is expected to grow at a CAGR of 25.5% from 2018 to 2025, reaching the value of $49.74 billion (http://ibn.fm/X87jS). Given these impressive growth rates, investors have been investing heavily in 3D-printing companies now that their commercial applications are soaring. The sector has already produced three unicorns, with the highest valued being Carbon, a 3D-printing, venture-backed startup that has raised $680 million, at a valuation of $2.4 billion, from investors such as Sequoia Capital, Madrone, Baillie Gifford Capital Partners and GV.

Sigma Labs was founded in 2010 and has since become the go-to, 3D-printing expert for real-time, computer-aided inspection (CAI) solutions. Managed by experts from many different science disciplines such as metallurgy, physics, signal processing, mechanical engineering, optics, software AI and ML, data analytics and visualization, the company established credibility within highly demanding industries such as aerospace, defense, biomedical and transportation.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sigma Labs Inc. SGLB | Leave a comment

MissionIRNewsBreaks – Youngevity International Inc. (NASDAQ: YGYI) to Serve as Premier Sponsor, Present at the 12th Annual LD Micro Main Event; Subsidiary to Serve as Lead Sponsor of MJ Biz Con

Youngevity International (NASDAQ: YGYI), a leading omni-direct lifestyle company, this morning announced that it will be presenting at the 12th annual LD Micro Main Event on Wednesday, December 11 at 11:20 AM PST. YGYI president and CFO Dave Briskie will be presenting in front of a variety of institutional investors, family offices, and high net worth investors. In addition, Youngevity will serve as a premier sponsor of the event featuring Be the Change(TM) coffee and Josies Java House Coffee, two of the company owned brands. “LD Micro continues to be an integral part of our awareness campaign and we are proud to be a premier sponsor, once again, for this year’s Main Event,” Youngevity president and CFO Dave Briskie stated in the news release. The Youngevity presentation will be available for 90 days following the live presentation (http://ibn.fm/5jUWc).

In addition, YGYI’s wholly-owned subsidiary, Khrysos Industries, Inc., this morning announced its participation as a lead sponsor at MJ Biz Con, the largest USA-based cannabis conference, which will take place in the Las Vegas Convention Center on December 11, 12, and 13. As a sponsor, Khrysos will feature a digital marketing piece that will be played on 12 screens 48 times a day. The conference is expected to draw an attendance of over 35,000 people from more than 70 countries including 1,500 CEO’s, 8,000 industry high level executives, and an expected attendance of over 1,250 cannabis industry investors. “We are proud to be sponsoring the MJ Biz Con conference this year,” Khrysos Industries president Dwayne Dundore PhD stated in the news release. “We will have our high-speed filtration systems, our KG250 hyper supercritical Co2 extraction system, a dual flask 50L rotary evaporator with HMI, a single stage stainless steel molecular wiped film distillation system and welch pumps and various displays featuring the capabilities of our vertical operation.”

To view the full press releases, visit http://ibn.fm/999kf and http://ibn.fm/UD7Ss

About Youngevity International, Inc.

YGYI, Inc. (NASDAQ: YGYI), is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, YGYI offers products from the eight top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, fashion, essential oils, photo, as well as innovative services. The company was formed in the course of the summer 2011 merger of Youngevity Essential Life Sciences with Javalution(R) Coffee company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For investor information, please visit www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Youngevity International Inc. YGYI | Leave a comment